Objectives: Combination therapies have a distinct advantage over monotherapies in terms of their broad spectrum, synergistic effect and prevention of the emergence of drug resistance. In the present study, the in vitro antibacterial activity of daptomycin combinations with linezolid and dalbavancin, and dalbavancin with linezolid were evaluated against 30 clinical MRSA strains.
Introduction
The antibiotic management of invasive Staphylococcus aureus infections has become quite complex over the past two decades because of the widespread prevalence of multiple antimicrobialresistant pathogens, including MRSA, intermediate vancomycinresistant S. aureus (VISA) and high-level vancomycin-resistant S. aureus (VRSA), which develop during vancomycin therapy. The increasing prevalence of MDR Gram-positive cocci requires the need to search for more effective agents. 1, 2 Antibiotics are sometimes used in combination in an attempt to prevent or delay the in vivo emergence of drug-resistant subpopulations of the pathogenic organism during therapy. With the simultaneous use of two or more antimicrobials against bacteria that develop resistance through different mechanisms, the probability that colonies will exhibit resistance to all of the currently employed antimicrobials is theoretically very low. Thus, simultaneous treatment with multiple drugs clearly reduces the risk of resistance during therapy. 3 Daptomycin is a lipopeptide antibiotic that disrupts bacterial cell membrane potential and permeability in a calciumdependent manner, leading to bacterial cell death via mechanisms that are not entirely clear. 4 The use of daptomycin has become relatively widespread over the past decade, and a number of clinical reports have documented the in vivo development of daptomycin resistance. 5, 6 Dalbavancin is a new, semisynthetic, second-generation lipoglycopeptide. Its spectrum of antibacterial activity is similar to that of other glycopeptides, but it is more potent in vitro than vancomycin and teicoplanin against susceptible and MDR Gram-positive bacteria including MRSA and methicillin-resistant CoNS, with the exception of VRE that have the VanA phenotype. 7, 8 Linezolid is an oxazolidinone antibiotic used for the treatment of infections caused by Gram-positive pathogens. 9 The rapid development of resistance to some of these newer agents has already been reported and this trend increases the importance of the further need for effective antimicrobial agents. 5, 6, 8 Combination therapies have a distinct advantage over monotherapies in terms of their broad spectrum, synergistic effect and ability to prevent or restrict the emergence of drug resistance. 3 In the present study, the in vitro antibacterial activity of daptomycin combined with linezolid and dalbavancin, and dalbavancin combined with linezolid was evaluated against 30 MRSA strains.
Materials and methods
Thirty clinical MRSA strains that were randomly selected were included in the study. Each strain was isolated from different patients who were Bacterial identifications and the presence of methicillin resistance were determined using conventional methods. The antibiotics used in the study were daptomycin (Novartis Pharma AG, Switzerland), linezolid (Pfizer Inc., Groton, CT, USA) and dalbavancin (Pfizer Inc., Groton, CT, USA); each was provided by the manufacturer.
In all microdilution tests, Mueller-Hinton broth (MHB; Difco Laboratories, Detroit, MI, USA) supplemented with divalent cations (CAMHB) to a final concentration of 10-12.5 mg/L Mg 2+ and 20-25 mg/L Ca 2+ (50 mg/L for daptomycin) was used. Additionally, in the tests for dalbavancin, CAMHB with 0.002% polysorbate 80 (Tween 80; Merck, Darmstadt, Germany) was used. The antibiotic concentrations tested were 0.03-16 mg/L for daptomycin and 0.008-4 mg/L for both dalbavancin and linezolid. The MICs of all antibiotics were determined using reference broth microdilution as described by the CLSI. 10 The MIC was defined as the lowest concentration of antimicrobial that gave complete inhibition of visible growth and was interpreted according to CLSI 11 and FDA 7 criteria. Quality control of test procedures was performed via testing of the reference strains S. aureus ATCC 29213 and Enterococcus faecalis ATCC 29212.
The in vitro activities of antibiotics in combination were assessed using a microbroth chequerboard assay. 3 The concentration range of each antibiotic used in the combinations was set as 2 dilutions above and 4 dilutions below the MIC of each drug. Thus, the chequerboard consisted of columns of wells, each containing the same amount of the drug being diluted in serial 2-fold increments along the x-axis, and rows in which each well contained the same amount of the two-drug combination, which was diluted along the y-axis in a two-dimensional chequerboard format. In the microtitre plate, each well contained a unique combination of the two antibiotics. Each drug tested in combination was also tested by itself. It was inoculated with a 24 h culture of each strain diluted to give a final concentration of approximately 5×10 5 cfu/mL. After overnight incubation of the plates at 358C, the MIC of each antibiotic combination was noted at the lowest dilution of the antibiotic combination that permitted no visible growth.
The fractional inhibitory concentration (FIC) index (FICI) was calculated for each combination using the following formula: FIC A +FIC B ¼ FICI, where FIC A ¼ MIC of drug A in combination/MIC of drug A alone and FIC B ¼MIC of drug B in combination/MIC of drug B alone. The FICI results were interpreted as follows: synergy ¼FICI ≤0.5; no interaction¼FICI .0.5 to 4; and antagonism ¼FICI .4.
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Results
The MIC values of antimicrobial agents for the 30 MRSA strains and the susceptibility rates are summarized in Table 1 .
All strains (100%) were susceptible to daptomycin, dalbavancin and linezolid. The MIC 50 , MIC 90 and MIC range values of antibiotics were established as 1, 1 and 0.5 -1 mg/L, 0.12, 0.12 and 0.03-0.12 mg/L, and 1, 2 and 1 -2 mg/L, respectively.
The distributions of FICI values of the combinations tested are summarized in Table 2 .
Our chequerboard assay results showed that the highest frequency of synergistic effects was for the two combinations dalbavancin + daptomycin and daptomycin +linezolid [67% (20/ 30)] followed by dalbavancin +linezolid [60% (18/30)].
The rates of no interaction were found to be 33% (10/30), 33% (10/30) and 40% (12/30), in the same order. No in vitro antagonism was observed. Discussion S. aureus has been able to acquire resistance to antimicrobial agents such as vancomycin, linezolid and daptomycin alone due to its propensity to evolve and adapt to its host and applied treatments. In our study, all MRSA strains were found to be susceptible to the antibiotics. The MIC 50 , MIC 90 and MIC range values of daptomycin, dalbavancin and linezolid were established as 1, 1 and 0.5 -1 mg/L, 0.12, 0.12 and 0.03 -0.12 mg/L, and 1, 2 and 1 -2 mg/L, respectively.
Dalbavancin, linezolid and daptomycin are new antibiotics that are effective in the therapy of MRSA infections. As such, they are unique antibiotics that are an alternative to vancomycin. Antibiotic combination studies allow exploration of different molecular targets of individual agents and thereby broaden the spectrum of action if there is synergy. 15 Therefore, some infection treatment strategies can be developed based on sets of drugs, rather than a single drug, by using data from in vitro/in vivo antimicrobial combination studies.
Parra-Ruiz et al. 16 evaluated in vitro linezolid/daptomycin against MRSA strains in biofilms. They reported that a combination of linezolid plus daptomycin was more effective than each agent alone, which represented another potential option in treatment. In another study, in vitro daptomycin/linezolid was noted to be effective against clinical daptomycin-non-susceptible MRSA strains. 17 However, Kelesidis et al. 18 reported that the combination of linezolid with daptomycin against MRSA showed indifference in chequerboard analysis and antagonism in time-kill assays.
Our combination test results showed that the highest rate of synergistic effect was 67% (20/30) for daptomycin combinations (i.e. daptomycin + dalbavancin and daptomycin + linezolid) followed by dalbavancin +linezolid [60% (18/30)]. There are no data on the effects of dalbavancin combined with linezolid and daptomycin. Our results may be the first on the in vitro effects of these two combinations. The results suggest that the in vitro effects of both combinations were highly synergistic (60% and 67%, respectively), with no antagonistic effect. However, further in vitro/in vivo studies are needed to elucidate the efficacy of the combinations tested.
Although they were effective against MRSA alone, the use of these antibiotics in combination may prevent or delay the growth of resistant mutant strains, which is important for the treatment of serious infections caused by Gram-positive pathogens.
Our findings suggest that these drugs might have a synergistic effect when used together, and might prevent or delay the emergence of resistance to these newer agents, which are among the few alternatives to vancomycin for the treatment of infections caused by MRSA today. 
